Pharmacogenomics Corner

Back to articles

Role of genotype-guided warfarin dosing for longer-term therapy

KEY POINT

Compared with standard dosing, genotype-guided warfarin dosing resulted in a greater time in therapeutic range (TTR) and a lower incidence of major bleeding in patients on therapy for more than 1 month, but no differences in these outcomes were observed between the two dosing strategies for shorter-term warfarin therapy (i.e., <1 mo of follow-up), according to results of a large meta-analysis published in CHEST